Pharmaceutical combination and use thereof
US-2024189341-A1 · Jun 13, 2024 · US
Multiple variants of meningococcal protein NBM1870
US8980286B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980286-B2 |
| Application number | US-201213364264-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 1, 2012 |
| Priority date | Nov 22, 2002 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising an aluminum salt adjuvant, a histidine buffer, and at least two of the following isolated antigens: (a) a first isolated protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 24; (b) a second isolated protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 33; and (c) a third isolated protein, comprising an amino acid sequence having at least 85% iden…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
- A61K39/095Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8980286B2 cover?
- Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal …
- Who is the assignee on this patent?
- Comanducci Maurizio, Pizza Mariagrazia, Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K39/095. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).